BMEA (Biomea Fusion Inc) Earnings per share for the last four quarters

Biomea (BMEA) - corporate logo

Biomea Fusion, Inc. (BMEA) focuses on the therapy of metabolic disorders and oncology. Scientific partnerships with universities help the company restore cellular functions. This daily price chart reflects the earnings per share, which stands at 87.90. Proprietary patents for menin inhibitors and strict FDA oversight block competitors from entering the niche. Meanwhile, a portion of the research is delegated to external laboratories without the loss of intellectual property rights.

BMEA biomeafusion.com Net earnings per share (EPS TTM) (02/11/2024 - 11/17/2026)

BMEA (Biomea Fusion, Inc.): analytical breakdowns and indicator data

- price and consensus price forecast:
- business market valuation indicators:
Fundamental company valuation:BMEA (Biomea Fusion Inc)
Core merchandise of Biomea Fusion Corp

An issuer's long-term reliability is determined by its ability to consistently grow earnings per share. This metric measures the annual growth rate of profit, allowing for an assessment of the business's capitalization efficiency. By analyzing the EPS YoY percentage change over 12 months, an investor can see the real dynamics of value creation. For Biomea Fusion, Inc. (BMEA), which is in the clinical trial stage without current revenues, this indicator confirms the company's dependence on external financing.

Competitor analysis

Net earnings per one share for the last twelve months Ascendis Pharma Inc.|MDGL (Madrigal Pharmaceuticals, Inc.) - Net earnings per share for the last 12 months|CORT: Earnings per share for the last four quarters|RYTM (Rhythm Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Akero Therapeutics|Net earnings per share (EPS TTM) MTSR|Earnings per share for the last twelve months MLTX (MoonLake Immunotherapeutics AG)|Earnings per share for the last twelve months crinetics.com CRNX|NewAmsterdam Pharma Corp (NAMS) - Net earnings per one share for the last twelve months|SLNO - Earnings per share for the last twelve months|FOLD: Earnings per share for the last twelve months|ETNB: Net earnings per share (EPS TTM)|AGIO - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Structure Corp|MiMedx Corp (MDXG) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months rezolutebio.com (RZLT)|Net earnings per share for the last 12 months lexpharma.com LXRX|Net earnings per share (EPS TTM) MBX (MBX Biosciences)|Altimmune Corp - Earnings per share for the last twelve months|Aardvark Therapeutics Inc. - Net earnings per share (EPS TTM)|SGMT - Net earnings per share (EPS TTM)|BioAge Labs (BIOA) - Earnings per share for the last twelve months|QNCX - Net earnings per share for the last four quarters|GUTS (Fractyl Health Inc.) - Net earnings per share (EPS TTM)|VTVT: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ATPC|Net earnings per share for the last four quarters Pluri Inc|Net earnings per share (EPS TTM) SYBX (Synlogic Corp)|Net earnings per share for the last four quarters lipocine.com (LPCN)|MTNB - Earnings per share for the last twelve months|Earnings per share for the trailing year SPRB (Spruce Biosciences)|GLTO (Galecto Corp) - Net earnings per share for the last 12 months|Carmell Corp - Earnings per share for the trailing year|LUMO (Lumos Therapeutics) - Net earnings per share (EPS TTM)|ONVO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) RDUS